Special Design for (S)-3-Amino-3-phenylpropionic Acid - LCZ696 Intermediate CAS 1426129-50-1 Purity ≥98.0% (HPLC) e.e ≥99.0% (R)-tert-Butyl (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate – Ruifu

Manufacturer with High Purity and Stable Quality
Commercial Supply LCZ696 (CAS: 936623-90-4) Related Intermediates:
(R)-tert-Butyl (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate CAS: 1426129-50-1
(R,E)-5-(1,1′-biphenyl-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid CAS: 1012341-48-8
(2R,4S)-5-(1,1′-biphenyl-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid CAS: 1012341-50-2
(2R,4S)-ethyl 5-(1,1′-biphenyl-4-yl)-4-amino-2-methylpentanoate HCl CAS: 149690-12-0
AHU-377 (hemicalcium salt) CAS: 1369773-39-6
AHU-377; Sacubitril CAS: 149709-62-6
LCZ696; Entresto; Sacubitril mixture with Valsartan CAS: 936623-90-4

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Manufacturer with High Purity and Stable Quality
Commercial Supply LCZ696 (CAS: 936623-90-4) Related Intermediates:
(R)-tert-Butyl (1-([1,1-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate CAS: 1426129-50-1
(R,E)-5-(1,1′-biphenyl-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid CAS: 1012341-48-8
(2R,4S)-5-(1,1′-biphenyl-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid CAS: 1012341-50-2
(2R,4S)-ethyl 5-(1,1′-biphenyl-4-yl)-4-amino-2-methylpentanoate HCl CAS: 149690-12-0
AHU-377 (hemicalcium salt) CAS: 1369773-39-6
AHU-377; Sacubitril CAS: 149709-62-6
LCZ696; Entresto; Sacubitril mixture with Valsartan CAS: 936623-90-4

LCZ696 a drug developed by Novartis Pharmaceutical of the United States for the treatment of heart failure. Heart failure is a life-threatening disease. The patient’s heart cannot pump enough blood to supply the body, and appear the symptoms of dyspnea, fatigue and fluid retention slowly, then gradually increased, significantly affect the quality of life. LCZ696 is a dual-acting angiotensin-receptor enkephalinase inhibitor that has a unique mechanism that is thought to reduce the strain of failing hearts. LCZ696 can enhance the body’s natural defense against heart failure, as well as increase the level of natriuretic peptides and other endogenous vasoactive peptides, and inhibit the renin-angiotensin-aldosterone system (RAAS). LCZ696 has combined with Novartis’s Hypertension Medication (Diovan, generic name: valsartan) and the experimental drug AHU-377. AHU377 blocks the mechanism of the two peptides responsible for lowering blood pressure. Diovan improves vasodilatation and stimulates the body to excrete sodium and water. LCZ696 is an experimental drug developed for the treatment of patients with Heart Failure with reduced Ejection Fraction (HFrEF). LCZ696, composed of valsartan and sacubitril in a 1: 1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for the treatment of hypertension and heart failure.